Parathyroid hormone therapy for hypoparathyroidism.

Abstract

Hypoparathyroidism is a disease characterized by hypocalcemia and insufficient parathyroid hormone (PTH). It is a rare disorder that has been given an orphan disease designation in the United States and European Union. Hypoparathyroidism is the only endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved therapy. Conventional therapy includes calcium and active vitamin D supplementation, often in large doses. Although serum calcium can be controlled with conventional therapy, it can be a challenge and, moreover, does not address other aspects of the disease, such as abnormal skeletal features and reduced quality of life. This review focuses on PTH replacement therapy in hypoparathyroidism, utilizing the full-length molecule PTH(1-84) as well as the fully active but truncated form PTH(1-34). PTH therapy addresses some aspects of the disease not ameliorated with conventional therapy.

• Authors: Natalie E Cusano, Mishaela R Rubin, John P Bilezikian
• Journal: Best practice & research. Clinical endocrinology & metabolism (Best Pract Res Clin Endocrinol Metab) Vol. 29 Issue 1 Pg. 47-55 (Jan 2015) ISSN: 1878-1594 [Electronic] Netherlands
• PMID: 25617172 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2014 Elsevier Ltd. All rights reserved.

Chemical References

• Parathyroid Hormone
• Vitamin D
• Calcium

Topics

• Calcium (therapeutic use)
• Hormone Replacement Therapy
• Humans
• Hypoparathyroidism (drug therapy)
• Parathyroid Hormone (therapeutic use)
• Treatment Outcome
• Vitamin D (therapeutic use)